This document aims to encourage countries to develop and implement policies to maintain and strengthen IPC programmes and measures in health care facilities in the context of the current ongoing transmission of the SARS-CoV-2, with recognition that epidemiological trends may vary and the risk of tra
...
nsmission of other pathogens.
more
Overview
• How are diseases transmitted from person to person?
• What are the principles of infection prevention and control
• What IPC measures are other countries / organisations recommending for the transport industry/workers?
• Ho
...
w can we apply this knowledge to protect us while we protect our country?
• Administrative controls = screening and awareness, people flow, health promotion
• Environmental controls = ventilation, airflow
• Personal protective equipment = use of masks, gloves, hand hygiene
more
The leishmaniases are a group of diseases caused by Leishmania spp., which occur in cutaneous, mucocutaneous and visceral forms. They are neglected tropical diseases (NTDs), which disproportionately affect marginalized populations who have limited access to health care. HIV co-infected patients with
...
Leishmania infection are highly infectious to sandflies, and an increase in the coinfection rate in an endemic area is likely to increase the effective infective reservoir.
more
16 Dec. 2021
This document is a prioritization toolkit providing a set of action steps to follow in the event of an impending surge in cases of COVID-19 in health-care facilities. The document provides a framework for action steps to be followed within 2-4 weeks of identification of a surge or resu
...
rgence of cases, and is accompanied by references to existing WHO resources to assist with managing each step. This document is intended for emergency operations centre focal persons for health facilities, incident managers, health-care managers and administrators, and infection prevention and control focal persons.
more
International Journal of Infectious Diseases 80 (2019) 10–15
journal homepage: www.elsevier.com/locate/ijid
15 January 2021
This Aide Memoire is for policy makers, immunization programme managers, infection prevention and control (IPC) focal points at national, sub-national, and facility level, as well as for health workers involved in COVID-19 vaccinati
...
on delivery. This document summarizes the key IPC principles to consider and the precautions to take for safely delivering COVID-19 vaccines. The principles and recommendations provided in this document derive from World Health Organization (WHO) IPC and immunization standards and other guidance in the context of COVID-19. WHO will update these recommendations as new information becomes available. All technical guidance for COVID-19 is available online.
more
Effective infection prevention and control (IPC) is the cornerstone of every health system. As of 2023, 17 Member States have a functioning IPC programme; 19 countries have developed national IPC guidelines; and 13 countries have adopted multimodel
...
intervention strategies to improve th
more
Preventive chemotherapy with praziquantel (PZQ) is the cornerstone of schistosomiasis control. However, a single dose of PZQ (40 mg/kg) does not cure all infections. Repeated doses of PZQ at short intervals might increase efficacy in terms of cure rate
...
(CR) and intensity reduction rate (IRR). Here, we determined the efficacy of a single versus four repeated treatments with PZQ on Schistosoma mansoni infection in school-aged children from Côte d'Ivoire, using two different diagnostic tests.
more
The Ministry of Health of Saudi Arabia has developed the guidelines to meet the urgent need for up -to-date information and evidence-based recommendations
Volumen 5 / Número 1 , 1025-1028 • http://www.revistabionatura.com
To describe the behavior of Tuberculosis/Human Immunodeficiency Virus co-infection in a cohort of people affected by sensitive Tuberculosis in Ecuador from 01 January 2010
...
to 31 December 2015. Results: The percentage of coinfected persons reached 11% in the whole period of study, with a range from 8.4% to 12.7%. Male sex shows the highest incidence rate, representing 76.7% at the rate of 1 man for every 3.3 women. The population with the highest incidence of patients is economically active; the age group of 25-34 years reaches 40.1%. The coastal zone of the country reports more than 75% of the coinfected patients. Conclusion: Increased HIV/AIDS screening should be increased for Tuberculosis, with particular emphasis on male sex and enhance the actions in the coastal provinces.
more
This chapter discusses the antibacterial treatment of leprosy infections. Antibiotic treatment is
a key component of leprosy treatment, as it is vital to prevent the progression of the infection.
Treatment with rifampin and other antibiotics is hi
...
ghly effective and cures 98% of patients with
the leprosy infection. Furthermore, the relapse rate is very low, at about 1% over 5–10 years.
There is little M. leprae drug resistance in leprosy and few reports of multi-drug resistance (1, 2, 3,
4, 5, 6, 7, 8). An antibiotic treatment may take months or years to produce clinical improvement,
especially in patients with an initial high bacterial index (BI).
more
In response to the COVID-19 outbreak, this guidance provides information on infection and prevention control (IPC) for older people, their friends and families, carers, and healthcare providers. Anyone who manages, works, volunteers or provides care
...
at any type of facilities where older people receive care at (long-term care facilities, non-acute care facilities, and home care services), should practice strict IPC to prevent and control COVID-19 outbreaks. It has been observed in different countries that older people have higher case-fatality rate compared to other age groups. Therefore, it is especially important to implement and follow IPC measures at facilities, homes, and other venues that older people frequent.
more
Iran J Public Health, Vol. 45, No.11, Nov 2016, pp.1521-1522
Country Progress Report January 2008 - December 2009
Over a period of two decades, under-5 mortality rate in Bangladesh has declined by 66% from 133 per 1000 live births in 1993-94 to 45 per 1000 live births in 2017-18. The country reached the MDG-4 goal in the reduction of child mortality on time. Ho
...
wever, the comparison of neonatal and under-5 mortality rates in Bangladesh over the same years reveals that the reduction in the neonatal mortality rate was much slower than the child mortality rate. This led to a rise in the proportion of neonatal deaths in overall under-five deaths from 40% in 1993-1994 to 67% percent in 2017-2018. More than 75% of neonatal deaths occur within the first 7 days. To achieve SDG target 3.2, Bangladesh has to further reduce under-5 mortality rate by 44% and newborn deaths by 60%. Infection is the leading cause of preventable deaths among the neonates and the young infants and the standard recommendations for treating severe bacterial infections in infants under 2 months of age include hospitalization and 7-10 days of parenteral therapy.
more
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for
...
hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more